176 related articles for article (PubMed ID: 16222881)
1. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study.
Ansaldi F; Turello V; Lai P; Bastone G; De Luca S; Rosselli R; Durando P; Sticchi L; Gasparini R; Delfino E; Icardi G
J Int Med Res; 2005; 33(5):490-500. PubMed ID: 16222881
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
5. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of pneumococcal polysaccharide vaccine in older patients with chronic respiratory diseases].
Watanuki Y; Takahashi H; Ogura T; Miyazawa N; Nakamura M; Hashizume T; Kozawa S; Tagawa A
Nihon Kokyuki Gakkai Zasshi; 2006 Apr; 44(4):305-11. PubMed ID: 16681246
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
9. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events.
Ihara H; Kikuchi K; Taniguchi H; Fujita S; Tsuruta Y; Kato M; Mitsuishi Y; Tajima K; Kodama Y; Takahashi F; Takahashi K; Azuma N
Vaccine; 2019 Oct; 37(43):6447-6453. PubMed ID: 31526624
[TBL] [Abstract][Full Text] [Related]
10. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.
Christenson B; Hedlund J; Lundbergh P; Ortqvist A
Eur Respir J; 2004 Mar; 23(3):363-8. PubMed ID: 15065822
[TBL] [Abstract][Full Text] [Related]
11. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
De Graeve D; Verhaegen J; Ament A; Baltussen R
Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
[TBL] [Abstract][Full Text] [Related]
13. [Pneumococcal vaccination for children and adults].
Albrich W
Ther Umsch; 2016; 73(5):235-40. PubMed ID: 27268445
[TBL] [Abstract][Full Text] [Related]
14. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
15. [Medical indications and effectiveness of the pneumococcal conjugate vaccine].
Reinert RR
Laryngorhinootologie; 2006 Apr; 85(4):291-8; quiz 299-300. PubMed ID: 16615030
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.
Domínguez A; Castilla J; Godoy P; Delgado-Rodríguez M; Saez M; Soldevila N; Astray J; Mayoral JM; Martín V; Quintana JM; González-Candelas F; Galán JC; Tamames S; Castro A; Baricot M; Garín O; Pumarola T;
Hum Vaccin Immunother; 2013 Apr; 9(4):865-73. PubMed ID: 23563516
[TBL] [Abstract][Full Text] [Related]
19. [23-valent pneumococcal vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society: February 2010].
Ripoll M E; Valenzuela B MT; Vergara F R; Abarca V K; Muñoz M A; Jiménez de la Jara J; Pinto C ME; Luchsinger F V
Rev Chilena Infectol; 2010 Apr; 27(2):133-7. PubMed ID: 20556313
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
